Difference between revisions of "Bicalutamide (Casodex)"

Revision as of 13:10, 10 December 2021

General information

Class/mechanism: Antiandrogen; non-steroidal androgen receptor inhibitor that competitively inhibits androgens by binding to cytosol androgen receptors.^[1]^[2]
Route: PO
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape UpToDate (courtesy of Lexicomp), or the prescribing information.^[1]

Diseases for which it is used

Prostate cancer

Patient drug information

History of changes in FDA indication

10/4/1995: Initial accelerated approval for use in combination therapy with a luteinizing-hormone releasing hormone (LHRH) analogue for the treatment of advanced prostate cancer.
- 12/12/1997: Converted to regular approval.
5/11/2005: Indicated for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analogue for the treatment of Stage D2 metastatic carcinoma of the prostate.

Also known as

Brand names: Casodex, Cosudex, Calutide, Kalumid

References

[insert-1] 1.0 ^1.1 ^1.2 Bicalutamide (Casodex) package insert

[2] Bicalutamide (Casodex) package insert (locally hosted backup)

[3] Bicalutamide (Casodex) patient drug information (Chemocare)

[4] Bicalutamide (Casodex) patient drug information (UpToDate)

[1]

[2]

[3]

[4]

@@ Line 15: / Line 15: @@
 ==History of changes in FDA indication==
-*10/4/1995: Initial FDA approval for use in combination therapy with a luteinizing-hormone releasing hormone (LHRH) analogue for the treatment of advanced [[prostate cancer]]
+*10/4/1995: Initial accelerated approval for use in combination therapy with a luteinizing-hormone releasing hormone (LHRH) analogue for the treatment of advanced [[prostate cancer]].
-*5/11/2005: Indicated for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analogue for the treatment of Stage D2 metastatic [[Prostate cancer | carcinoma of the prostate]].
+**12/12/1997: Converted to regular approval.
+*5/11/2005: Indicated for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analogue for the treatment of Stage D2 metastatic [[Prostate cancer | carcinoma of the prostate]].
 ==Also known as==